Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

32.27 +0.36 (+1.11%)
Streaming Delayed Price Updated: 2:12 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
ALKERMES PLC (NASDAQ:ALKS) – A Potential Undervalued Opportunity in Biopharma ↗
ALKERMES PLC (NASDAQ:ALKS) shows strong profitability and financial health while trading at a discount to peers, making it a potential value opportunity in biopharma. 
Via Chartmill
News headline image
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
NASDAQ:ALKS: good value for what you're paying. ↗
Uncover the potential of ALKERMES PLC, an undervalued stock. NASDAQ:ALKS maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
News headline image
Earnings Scheduled For February 12, 2025 ↗
 
Via Benzinga
News headline image
Despite its impressive fundamentals, NASDAQ:ALKS remains undervalued. ↗
ALKERMES PLC (NASDAQ:ALKS) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
News headline image
Earnings Scheduled For July 29, 2025 ↗
 
Via Benzinga
News headline image
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. ↗
All four companies are testing out orexin agonists to improve the symptoms of narcolpesy. 
Via Investor's Business Daily
News headline image
Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study ↗
Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability across all doses. 
Via Benzinga
News headline image
Expert Outlook: Alkermes Through The Eyes Of 6 Analysts ↗
 
Via Benzinga
News headline image
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
News headline image
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
NASDAQ:ALKS, an undervalued stock with good fundamentals. ↗
ALKERMES PLC (NASDAQ:ALKS): good value for what you're paying. 
Via Chartmill
News headline image
NASDAQ:ALKS: good value for what you're paying. ↗
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
Beyond The Numbers: 6 Analysts Discuss Alkermes Stock ↗
 
Via Benzinga
News headline image
In a market where value is scarce, ALKERMES PLC (NASDAQ:ALKS) offers a refreshing opportunity with its solid fundamentals. ↗
ALKERMES PLC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:ALKS showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
News headline image
What 5 Analyst Ratings Have To Say About Alkermes ↗
 
Via Benzinga
News headline image
Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday? ↗
A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New... 
Via Benzinga
Topics Economy
News headline image
A Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts ↗
 
Via Benzinga
News headline image
NASDAQ:ALKS is an undervalued gem with solid fundamentals. ↗
ALKERMES PLC (NASDAQ:ALKS), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
Alkermes Plc EPS Soars Past Forecasts ↗
Alkermes reported strong earnings by exceeding both revenue and earnings expectations in its latest quarterly release. 
Via The Motley Fool
News headline image
NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
When you look at ALKERMES PLC (NASDAQ:ALKS), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Alkermes's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Decoding 7 Analyst Evaluations For Alkermes ↗
 
Via Benzinga
News headline image
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits ↗
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.